BioNTech SE (BNTX) EV/Sales Ratio: 4.37x
Is BioNTech SE’s EV/Sales ratio high or low?
BioNTech SE's EV/Sales ratio of 4.37x is in line with its 5-year average of 4.12x, near the low end of its 5-year range (0.92x–24.54x).
The EV/Sales ratio for BioNTech SE (BNTX) is 4.37x as of Tuesday, June 9, 2026. It is below its 12-month average by 15.78% (5.19x).
BNTX EV/Sales Ratio Chart
BNTX Average EV/Sales Ratio Chart
BNTX Current vs Average EV/Sales Ratio Chart
BNTX EV/Sales Ratio Metrics
EV/SALES RATIO
4.37x
EV/SALES RATIO AVG TTM
5.19x
EV/SALES RATIO AVG 3Y
4.38x
EV/SALES RATIO AVG 5Y
4.12x
EV/SALES RATIO AVG 10Y
23.27x
EV/SALES RATIO AVG 15Y
23.27x
EV/SALES RATIO AVG 20Y
23.27x
CURRENT VS TTM AVG
-15.78%
CURRENT VS 3Y AVG
-0.26%
CURRENT VS 5Y AVG
+6.15%
CURRENT VS 10Y AVG
-81.22%
CURRENT VS 15Y AVG
-81.22%
CURRENT VS 20Y AVG
-81.22%
BNTX Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | — | 4.37x | 5.19x | 4.38x | 4.12x |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 6.30x | 7.35x | 7.52x | 8.18x |
| Waters Corporation (WAT) | $24.19B | 9.44x | 7.02x | 7.12x | 7.32x |
| Moderna, Inc. (MRNA) | $18.94B | 8.20x | 5.92x | 5.01x | 6.86x |
| Hologic, Inc. (HOLX) | $16.97B | 4.25x | 4.02x | 4.39x | 4.15x |
| Veeva Systems Inc. (VEEV) | $27.37B | 7.85x | 12.54x | 13.33x | 15.72x |
| Biogen Inc. (BIIB) | $29.39B | 3.32x | 2.78x | 3.30x | 3.58x |
| DexCom, Inc. (DXCM) | $30.17B | 6.44x | 6.65x | 10.24x | 13.90x |
| Align Technology, Inc. (ALGN) | $12.76B | 2.88x | 2.73x | 4.08x | 5.93x |
| IQVIA Holdings Inc. (IQV) | $31.09B | 1.91x | 2.84x | 3.22x | 3.53x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
BioNTech SE EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE EV/Sales Ratio FAQ
- What is the EV/Sales ratio for BioNTech SE (BNTX)?
- The EV/Sales ratio for BNTX stock is 4.37x.
- Is BioNTech SE's EV/Sales ratio high or low?
- BioNTech SE's EV/Sales ratio of 4.37x is in line with its 5-year average of 4.12x, near the low end of its 5-year range (0.92x–24.54x).
- What is the TTM average EV/Sales ratio for BioNTech SE (BNTX)?
- The TTM average EV/Sales ratio for BNTX stock is 5.19x.
- What is the 3Y average EV/Sales ratio for BioNTech SE (BNTX)?
- The 3Y average EV/Sales ratio for BNTX stock is 4.38x.
- What is the 5Y average EV/Sales ratio for BioNTech SE (BNTX)?
- The 5Y average EV/Sales ratio for BNTX stock is 4.12x.
- What is the 10Y average EV/Sales ratio for BioNTech SE (BNTX)?
- The 10Y average EV/Sales ratio for BNTX stock is 23.27x.
- What is the 15Y average EV/Sales ratio for BioNTech SE (BNTX)?
- The 15Y average EV/Sales ratio for BNTX stock is 23.27x.
- What is the 20Y average EV/Sales ratio for BioNTech SE (BNTX)?
- The 20Y average EV/Sales ratio for BNTX stock is 23.27x.
BioNTech SE EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-09 | 4.37x |
| 2026-06-08 | 4.28x |
| 2026-06-05 | 4.51x |
| 2026-06-04 | 4.65x |
| 2026-06-03 | 4.55x |
| 2026-06-02 | 4.61x |
| 2026-06-01 | 4.84x |
| 2026-05-29 | 5.22x |
| 2026-05-28 | 5.00x |
| 2026-05-27 | 4.96x |
| 2026-05-26 | 4.89x |
| 2026-05-22 | 4.88x |
| 2026-05-21 | 4.77x |
| 2026-05-20 | 4.72x |
| 2026-05-19 | 4.49x |
| 2026-05-18 | 4.58x |
| 2026-05-15 | 4.64x |
| 2026-05-14 | 4.87x |
| 2026-05-13 | 4.89x |
| 2026-05-12 | 5.02x |
| 2026-05-11 | 4.99x |
| 2026-05-08 | 5.06x |
| 2026-05-07 | 4.96x |
| 2026-05-06 | 5.16x |
| 2026-05-05 | 5.18x |
| 2026-05-04 | 5.92x |
| 2026-05-01 | 5.77x |
| 2026-04-30 | 6.28x |
| 2026-04-29 | 6.11x |
| 2026-04-28 | 6.16x |
| 2026-04-27 | 6.16x |
| 2026-04-24 | 6.45x |
| 2026-04-23 | 6.46x |
| 2026-04-22 | 6.72x |
| 2026-04-21 | 6.97x |
| 2026-04-20 | 6.42x |
| 2026-04-17 | 6.23x |
| 2026-04-16 | 6.16x |
| 2026-04-15 | 5.93x |
| 2026-04-14 | 5.84x |
| 2026-04-13 | 5.70x |
| 2026-04-10 | 5.59x |
| 2026-04-09 | 5.29x |
| 2026-04-08 | 5.30x |
| 2026-04-07 | 5.09x |
| 2026-04-06 | 5.23x |
| 2026-04-02 | 5.22x |
| 2026-04-01 | 5.07x |
| 2026-03-31 | 5.03x |
| 2026-03-30 | 4.72x |
| 2026-03-27 | 4.75x |
| 2026-03-26 | 4.91x |
| 2026-03-25 | 5.02x |
| 2026-03-24 | 4.85x |
| 2026-03-23 | 4.99x |
| 2026-03-20 | 5.06x |
| 2026-03-19 | 5.06x |
| 2026-03-18 | 5.12x |
| 2026-03-17 | 5.54x |
| 2026-03-16 | 5.17x |
| 2026-03-13 | 5.23x |
| 2026-03-12 | 5.13x |
| 2026-03-11 | 5.20x |
| 2026-03-10 | 4.60x |
| 2026-03-09 | 4.63x |
| 2026-03-06 | 4.58x |
| 2026-03-05 | 4.61x |
| 2026-03-04 | 4.75x |
| 2026-03-03 | 4.52x |
| 2026-03-02 | 5.03x |
| 2026-02-27 | 5.24x |
| 2026-02-26 | 5.13x |
| 2026-02-25 | 5.21x |
| 2026-02-24 | 5.29x |
| 2026-02-23 | 5.22x |
| 2026-02-20 | 5.23x |
| 2026-02-19 | 5.25x |
| 2026-02-18 | 5.07x |
| 2026-02-17 | 4.99x |
| 2026-02-13 | 4.91x |
| 2026-02-12 | 4.90x |
| 2026-02-11 | 5.17x |
| 2026-02-10 | 5.14x |
| 2026-02-09 | 5.25x |
| 2026-02-06 | 4.97x |
| 2026-02-05 | 4.88x |
| 2026-02-04 | 5.13x |
| 2026-02-03 | 5.09x |
| 2026-02-02 | 5.14x |
| 2026-01-30 | 5.51x |
| 2026-01-29 | 5.74x |
| 2026-01-28 | 5.69x |
| 2026-01-27 | 5.93x |
| 2026-01-26 | 5.83x |
| 2026-01-23 | 5.68x |
| 2026-01-22 | 5.86x |
| 2026-01-21 | 5.83x |
| 2026-01-20 | 4.88x |
| 2026-01-16 | 5.15x |
| 2026-01-15 | 4.92x |
| 2026-01-14 | 5.15x |
| 2026-01-13 | 5.01x |
| 2026-01-12 | 4.63x |
| 2026-01-09 | 4.45x |
| 2026-01-08 | 4.38x |
| 2026-01-07 | 4.47x |
| 2026-01-06 | 4.32x |
| 2026-01-05 | 4.22x |
| 2026-01-02 | 4.21x |
| 2025-12-31 | 4.10x |
| 2025-12-30 | 4.10x |
| 2025-12-29 | 4.10x |
| 2025-12-26 | 4.05x |
| 2025-12-24 | 4.09x |
| 2025-12-23 | 4.02x |
| 2025-12-22 | 3.87x |
| 2025-12-19 | 3.89x |
| 2025-12-18 | 3.81x |
| 2025-12-17 | 3.83x |
| 2025-12-16 | 3.87x |
| 2025-12-15 | 3.99x |
| 2025-12-12 | 4.07x |
| 2025-12-11 | 4.16x |
| 2025-12-10 | 4.14x |
| 2025-12-09 | 4.15x |
| 2025-12-08 | 4.26x |
| 2025-12-05 | 4.18x |
| 2025-12-04 | 4.16x |
| 2025-12-03 | 4.21x |
| 2025-12-02 | 4.17x |
| 2025-12-01 | 4.26x |
| 2025-11-28 | 4.70x |
| 2025-11-26 | 4.67x |
| 2025-11-25 | 4.44x |
| 2025-11-24 | 4.20x |
| 2025-11-21 | 4.13x |
| 2025-11-20 | 4.23x |
| 2025-11-19 | 4.57x |
| 2025-11-18 | 4.65x |
| 2025-11-17 | 4.67x |
| 2025-11-14 | 4.70x |
| 2025-11-13 | 4.76x |
| 2025-11-12 | 5.35x |
| 2025-11-11 | 5.12x |
| 2025-11-10 | 4.85x |
| 2025-11-07 | 4.70x |
| 2025-11-06 | 4.72x |
| 2025-11-05 | 4.72x |
| 2025-11-04 | 4.83x |
| 2025-11-03 | 4.76x |
| 2025-10-31 | 5.25x |
| 2025-10-30 | 5.31x |
| 2025-10-29 | 5.20x |
| 2025-10-28 | 5.34x |
| 2025-10-27 | 5.43x |
| 2025-10-24 | 5.40x |
| 2025-10-23 | 5.32x |
| 2025-10-22 | 5.44x |
| 2025-10-21 | 5.50x |
| 2025-10-20 | 5.59x |
| 2025-10-17 | 5.35x |
| 2025-10-16 | 5.35x |
| 2025-10-15 | 5.28x |
| 2025-10-14 | 5.14x |
| 2025-10-13 | 5.11x |
| 2025-10-10 | 5.09x |
| 2025-10-09 | 5.30x |
| 2025-10-08 | 5.45x |
| 2025-10-07 | 5.43x |
| 2025-10-06 | 5.35x |
| 2025-10-03 | 5.38x |
| 2025-10-02 | 5.30x |
| 2025-10-01 | 5.11x |
| 2025-09-30 | 4.80x |
| 2025-09-29 | 4.76x |
| 2025-09-26 | 4.76x |
| 2025-09-25 | 4.76x |
| 2025-09-24 | 4.90x |
| 2025-09-23 | 4.78x |
| 2025-09-22 | 4.81x |
| 2025-09-19 | 4.60x |
| 2025-09-18 | 4.61x |
| 2025-09-17 | 4.77x |
| 2025-09-16 | 4.86x |
| 2025-09-15 | 4.74x |
| 2025-09-12 | 4.65x |
| 2025-09-11 | 5.28x |
| 2025-09-10 | 5.00x |
| 2025-09-09 | 5.10x |
| 2025-09-08 | 5.14x |
| 2025-09-05 | 5.97x |
| 2025-09-04 | 5.21x |
| 2025-09-03 | 4.96x |
| 2025-09-02 | 4.97x |
| 2025-08-29 | 4.92x |
| 2025-08-28 | 5.08x |
| 2025-08-27 | 5.17x |
| 2025-08-26 | 5.32x |
| 2025-08-25 | 5.35x |
| 2025-08-22 | 5.83x |
| 2025-08-21 | 5.82x |
| 2025-08-20 | 5.87x |
| 2025-08-19 | 5.88x |
| 2025-08-18 | 5.97x |
| 2025-08-15 | 6.06x |
| 2025-08-14 | 5.99x |
| 2025-08-13 | 5.99x |
| 2025-08-12 | 5.84x |
| 2025-08-11 | 5.70x |
| 2025-08-08 | 5.90x |
| 2025-08-07 | 5.87x |
| 2025-08-06 | 5.87x |
| 2025-08-05 | 5.85x |
| 2025-08-04 | 5.76x |
| 2025-08-01 | 5.79x |
| 2025-07-31 | 5.81x |
| 2025-07-30 | 6.03x |
| 2025-07-29 | 6.15x |
| 2025-07-28 | 6.27x |
| 2025-07-25 | 6.49x |
| 2025-07-24 | 6.42x |
| 2025-07-23 | 6.43x |
| 2025-07-22 | 6.15x |
| 2025-07-21 | 5.93x |
| 2025-07-18 | 6.03x |
| 2025-07-17 | 6.12x |
| 2025-07-16 | 6.24x |
| 2025-07-15 | 6.08x |
| 2025-07-14 | 6.11x |
| 2025-07-11 | 6.28x |
| 2025-07-10 | 6.37x |
| 2025-07-09 | 6.18x |
| 2025-07-08 | 6.17x |
| 2025-07-07 | 6.03x |
| 2025-07-03 | 6.02x |
| 2025-07-02 | 5.87x |
| 2025-07-01 | 5.81x |
| 2025-06-30 | 5.72x |
| 2025-06-27 | 5.74x |
| 2025-06-26 | 5.69x |
| 2025-06-25 | 5.57x |
| 2025-06-24 | 5.60x |
| 2025-06-23 | 5.41x |
| 2025-06-20 | 5.72x |
| 2025-06-18 | 5.53x |
| 2025-06-17 | 5.58x |
| 2025-06-16 | 5.70x |
| 2025-06-13 | 5.72x |
| 2025-06-12 | 5.58x |
| 2025-06-11 | 5.63x |
| 2025-06-10 | 5.75x |
| 2025-06-09 | 5.93x |
| 2025-06-06 | 5.89x |
| 2025-06-05 | 6.04x |
| 2025-06-04 | 6.13x |
| 2025-06-03 | 6.52x |
| 2025-06-02 | 6.30x |
| 2025-05-30 | 4.78x |
| 2025-05-29 | 5.17x |
| 2025-05-28 | 4.93x |
Showing the most recent 260 of 1,674 data points. The chart above shows the full history.
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin